# Impact of Peptides and Chelators on Somatostatin Receptor Antagonists

> **NCT04491851** · PHASE2 · UNKNOWN · sponsor: **Peking Union Medical College Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Neuroendocrine Tumors

## Interventions

- **DIAGNOSTIC_TEST:** 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 PET/CT
- **DIAGNOSTIC_TEST:** 68Ga-NODAGA-LM3 and 68Ga-NODAGA-JR11 PET/CT

## Key facts

- **NCT ID:** NCT04491851
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-10-01
- **Primary completion:** 2021-09
- **Final completion:** 2021-09
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2020-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04491851

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04491851, "Impact of Peptides and Chelators on Somatostatin Receptor Antagonists". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04491851. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*